Cortiment^® – first oral budesonide for the treatment of mild to middle active ulcerative colitis

Czech version

Authors: M. Lukáš
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha
Published in: Gastroent Hepatol 2016; 70(1): 95-96
Category: Drug Profile
doi: https://doi.org/10.14735/amgh201695

Sources

1. Ferring Pharmaceuticals. CORTIMENT 9 mg SPC. [online]. Available from: www.medicines.org.uk/emc/medicine/30253.

2. Sandborn WJ, Travis S, Moro L et al. Once-daily budesonide MMX^® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143(5): 1218– 1226. doi: 10.1053/ j.gastro.2012.08.003.

3. Travis SP, Danese S, Kupcinskas L et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63(3): 433– 441. doi: 10.1136/gutjnl-2012-304258.

4. Fiorino G, Fries W, De La Rue SA et al. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. Curr Med Chem 2010; 17(17): 1851– 1857.